Main Conference Day 3Wednesday, 17 December 2025 - PT (Pacific Time, GMT-08:00)

Radiotherapy remains a cornerstone of cancer treatment, yet its efficacy is often limited by normal tissue toxicity and tumor resistance. This talk will highlight a translational strategy to enhance radiotherapy by leveraging antibody-drug conjugates (ADCs) for targeted delivery of cytotoxic agents. I will present preclinical data demonstrating how ADCs directed against radiation-inducible tumor antigens potentiate tumor response, offering a precision-based approach to improve outcomes in solid tumors.